Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target

Laurence J Miller, Aditya J. Desai

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Cholecystokinin (CCK) regulates appetite and reduces food intake by activating the type 1 CCK receptor (CCK1R). Attempts to develop CCK1R agonists for obesity have yielded active agents that have not reached clinical practice. Here we discuss why, along with new strategies to target CCK1R more effectively. We examine signaling events and the possibility of developing agents that exhibit ligand-directed bias, to dissociate satiety activity from undesirable side effects. Potential allosteric sites of modulation are also discussed, along with desired properties of a positive allosteric modulator (PAM) without intrinsic agonist action as another strategy to treat obesity. These new types of CCK1R-active drugs could be useful as standalone agents or as part of a rational drug combination for management of obesity. Cholecystokinin (CCK), acting though the type 1 CCK receptor (CCK1R) on vagal afferent neurons, is an important physiologic regulator of appetite. While potent receptor agonists have been developed, they have not reached clinical use due to limited efficacy and potential side effects and toxicity.Activation of CCK1R stimulates multiple interacting signaling cascades initiated through the Gq family, G13, Gs, and arrestin. Biased agonists can potentially stimulate a subset of events responsible for satiety independent of events contributing to trophic and other side effects.Positive allosteric modulators without intrinsic agonist activity can potentially enhance the satiety effect of endogenous CCK-58 released during a meal, reducing meal size and extending intermeal intervals.New types of CCK1R-active drugs may be useful as standalone agents or as part of rational drug combinations.

Original languageEnglish (US)
JournalTrends in Endocrinology and Metabolism
DOIs
StateAccepted/In press - 2016

Fingerprint

Cholecystokinin Receptors
Obesity
Cholecystokinin
Appetite
Drug Combinations
Meals
Allosteric Site
Arrestin
Afferent Neurons
Pharmaceutical Preparations
Therapeutics
Eating
Ligands

Keywords

  • Biased agonists
  • Cholecystokinin
  • Positive allosteric modulators
  • Satiety
  • Type 1 cholecystokinin receptor

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{06bc3880f2ae44a9804472f4be0cec66,
title = "Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target",
abstract = "Cholecystokinin (CCK) regulates appetite and reduces food intake by activating the type 1 CCK receptor (CCK1R). Attempts to develop CCK1R agonists for obesity have yielded active agents that have not reached clinical practice. Here we discuss why, along with new strategies to target CCK1R more effectively. We examine signaling events and the possibility of developing agents that exhibit ligand-directed bias, to dissociate satiety activity from undesirable side effects. Potential allosteric sites of modulation are also discussed, along with desired properties of a positive allosteric modulator (PAM) without intrinsic agonist action as another strategy to treat obesity. These new types of CCK1R-active drugs could be useful as standalone agents or as part of a rational drug combination for management of obesity. Cholecystokinin (CCK), acting though the type 1 CCK receptor (CCK1R) on vagal afferent neurons, is an important physiologic regulator of appetite. While potent receptor agonists have been developed, they have not reached clinical use due to limited efficacy and potential side effects and toxicity.Activation of CCK1R stimulates multiple interacting signaling cascades initiated through the Gq family, G13, Gs, and arrestin. Biased agonists can potentially stimulate a subset of events responsible for satiety independent of events contributing to trophic and other side effects.Positive allosteric modulators without intrinsic agonist activity can potentially enhance the satiety effect of endogenous CCK-58 released during a meal, reducing meal size and extending intermeal intervals.New types of CCK1R-active drugs may be useful as standalone agents or as part of rational drug combinations.",
keywords = "Biased agonists, Cholecystokinin, Positive allosteric modulators, Satiety, Type 1 cholecystokinin receptor",
author = "Miller, {Laurence J} and Desai, {Aditya J.}",
year = "2016",
doi = "10.1016/j.tem.2016.04.002",
language = "English (US)",
journal = "Trends in Endocrinology and Metabolism",
issn = "1043-2760",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Metabolic Actions of the Type 1 Cholecystokinin Receptor

T2 - Its Potential as a Therapeutic Target

AU - Miller, Laurence J

AU - Desai, Aditya J.

PY - 2016

Y1 - 2016

N2 - Cholecystokinin (CCK) regulates appetite and reduces food intake by activating the type 1 CCK receptor (CCK1R). Attempts to develop CCK1R agonists for obesity have yielded active agents that have not reached clinical practice. Here we discuss why, along with new strategies to target CCK1R more effectively. We examine signaling events and the possibility of developing agents that exhibit ligand-directed bias, to dissociate satiety activity from undesirable side effects. Potential allosteric sites of modulation are also discussed, along with desired properties of a positive allosteric modulator (PAM) without intrinsic agonist action as another strategy to treat obesity. These new types of CCK1R-active drugs could be useful as standalone agents or as part of a rational drug combination for management of obesity. Cholecystokinin (CCK), acting though the type 1 CCK receptor (CCK1R) on vagal afferent neurons, is an important physiologic regulator of appetite. While potent receptor agonists have been developed, they have not reached clinical use due to limited efficacy and potential side effects and toxicity.Activation of CCK1R stimulates multiple interacting signaling cascades initiated through the Gq family, G13, Gs, and arrestin. Biased agonists can potentially stimulate a subset of events responsible for satiety independent of events contributing to trophic and other side effects.Positive allosteric modulators without intrinsic agonist activity can potentially enhance the satiety effect of endogenous CCK-58 released during a meal, reducing meal size and extending intermeal intervals.New types of CCK1R-active drugs may be useful as standalone agents or as part of rational drug combinations.

AB - Cholecystokinin (CCK) regulates appetite and reduces food intake by activating the type 1 CCK receptor (CCK1R). Attempts to develop CCK1R agonists for obesity have yielded active agents that have not reached clinical practice. Here we discuss why, along with new strategies to target CCK1R more effectively. We examine signaling events and the possibility of developing agents that exhibit ligand-directed bias, to dissociate satiety activity from undesirable side effects. Potential allosteric sites of modulation are also discussed, along with desired properties of a positive allosteric modulator (PAM) without intrinsic agonist action as another strategy to treat obesity. These new types of CCK1R-active drugs could be useful as standalone agents or as part of a rational drug combination for management of obesity. Cholecystokinin (CCK), acting though the type 1 CCK receptor (CCK1R) on vagal afferent neurons, is an important physiologic regulator of appetite. While potent receptor agonists have been developed, they have not reached clinical use due to limited efficacy and potential side effects and toxicity.Activation of CCK1R stimulates multiple interacting signaling cascades initiated through the Gq family, G13, Gs, and arrestin. Biased agonists can potentially stimulate a subset of events responsible for satiety independent of events contributing to trophic and other side effects.Positive allosteric modulators without intrinsic agonist activity can potentially enhance the satiety effect of endogenous CCK-58 released during a meal, reducing meal size and extending intermeal intervals.New types of CCK1R-active drugs may be useful as standalone agents or as part of rational drug combinations.

KW - Biased agonists

KW - Cholecystokinin

KW - Positive allosteric modulators

KW - Satiety

KW - Type 1 cholecystokinin receptor

UR - http://www.scopus.com/inward/record.url?scp=84964832355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964832355&partnerID=8YFLogxK

U2 - 10.1016/j.tem.2016.04.002

DO - 10.1016/j.tem.2016.04.002

M3 - Article

C2 - 27156041

AN - SCOPUS:84964832355

JO - Trends in Endocrinology and Metabolism

JF - Trends in Endocrinology and Metabolism

SN - 1043-2760

ER -